Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure

An immunomodulatory protein, a technology for chronic heart failure, which is applied in the application field of recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) in the preparation of drugs for the treatment of chronic heart failure, and can solve problems such as different clinical effects

Inactive Publication Date: 2014-05-28
张喜田 +1
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

3) β-receptor blockers, β-receptor blockers treat the pathophysiological basis of CHF - reduce myocardial oxygen consumption and improve cardiac function: However, different β-receptor blockers may have different effects on heart failure patients clinical effect
Receptor blockers are not indicated for acute heart failure and should only be used in stable conditions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure
  • Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure
  • Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the establishment of heart failure animal model

[0037] 1.1 Experimental method:

[0038] 1.1.1 Experimental materials and reagents

[0039] rLZ-8, doxorubicin hydrochloride, normal saline, disposable 1mL syringe, Shengmai injection, rat feed, litter.

[0040] 1.1.2 Instruments and equipment

[0041] Incandescent lamp, rat breeding cage, electronic balance, 4°C refrigerator, two-person ultra-clean workbench, ordinary optical inverted microscope.

[0042] 1.1.3 Experimental animals

[0043] Wistar rats, female, weighing 200-240 g, were provided by the Experimental Animal Center of Jilin University (Certificate No.: Yidongzi No. 10-5112).

[0044] 1.2 Establishment of rat heart failure model

[0045] Choose healthy and flexible Wistar rats, female, weighing 200-240g, SPF grade, refer to Teraoka's method, and give doxorubicin hydrochloride (diluted with normal saline) intraperitoneally to the rats in all groups except the blank group, the injection do...

Embodiment 2

[0046] Example 2: Therapeutic effect of rLZ-8 on rat chronic heart failure model

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure. According to the invention, a rat cardiac failure model is established by intraperitoneal injection of adriamycin amycin (ADR) to study the curative effect of rLZ-8 to chronic cardiac failure. Experimental research results show that rLZ-8 can remarkably improve the cardiac function of the rat cardiac failure model, reduce the rate of myocardial apoptosis, reduce expression of relevant apoptin in myocardial cells (caspase3 and caspase9) and increase the survival rate of rats with chronic heart failure.

Description

technical field [0001] The present invention relates to the application of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) in the preparation of drugs for the treatment of chronic heart failure, in particular to the establishment of rat models of chronic heart failure, the design of treatment procedures and the statistical analysis of treatment results, and involves rat myocardial Detection of cells and related proteins, focusing on the application of recombinant Ganoderma lucidum immunomodulatory proteins in the treatment of chronic heart failure models in rats. Background technique [0002] Chronic heart failure (CHF) is the most common form of heart failure. It is the end stage of the development of various cardiovascular diseases such as coronary heart disease, cardiomyopathy, hypertension, and valvular heart disease, and it is also the leading cause of death. With the aging of the population and the improvement of the diagnosis and treatment system for ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P9/04
CPCA61K36/074A61K38/168A61P9/04
Inventor 孙非梁重阳张喜田
Owner 张喜田
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com